ArticleBone marrow transplantation2020
A reproducible and safe at-home allogeneic haematopoietic cell transplant program: first experience in Central and Southern Europe.
Article in Bone marrow transplantation, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Economic Burden of Acute Myeloid Leukemia in European Union: Results from a Systematic Review of Literature.PharmacoEconomics - open · 2025Pooled it
- Pooled it
- Hospital at Home Following Allogeneic Hematopoietic Stem Cell Transplantation: An Economic Analysis.Healthcare (Basel, Switzerland) · 2025Article
- [Protective environment strategies for hematopoietic stem cell transplantation: progress and prospects].Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences · 2024Review
- Article
- Hematopoietic Stem Cell Transplantation Impact on Patients' Perceived Quality of Life: A Longitudinal Study.Nursing reports (Pavia, Italy) · 2024Article
- A comparison of haploidentical versus HLA-identical sibling outpatient hematopoietic cell transplantation using reduced intensity conditioning in patients with acute leukemia.Frontiers in immunology · 2024Article
- Brave new world: expanding home care in stem cell transplantation and advanced therapies with new technologies.Frontiers in immunology · 2024Review
- Better clinical outcomes and lower triggering of inflammatory cytokines for allogeneic hematopoietic cell transplant recipients treated in home care versus hospital isolation - the Karolinska experience.Frontiers in immunology · 2024Review
- Optimization of a home hospitalization program for hematopoietic stem cell transplantation with ehealth integration and clinical pharmacist involvement.Frontiers in immunology · 2024Article
- Post-Transplant Complications in Patients Undergoing Autologous Hematopoietic Cell Transplantation (HCT)-A Comparative Analysis of Home Care versus Hospitalized Patients.Medicina (Kaunas, Lithuania) · 2023Observational
- At-Home Foscarnet Administration in Patients with Cytomegalovirus Infection Post-Allogeneic Stem Cell Transplantation: A Unicentric, Safe, and Feasible Program.Pharmaceuticals (Basel, Switzerland) · 2023Article
- Outpatient allogeneic hematopoietic stem-cell transplantation: a review.Therapeutic advances in hematology · 2022Review
- Personalized at-home autologous hematopoietic stem cell transplantation during the SARS-CoV-2 outbreak.Leukemia research · 2021Article
- Cytokine levels following allogeneic hematopoietic cell transplantation: a match-pair analysis of home care versus hospital care.International journal of hematology · 2021Article
- Is there no place like home for an allogeneic stem cell transplant?Bone marrow transplantation · 2020Article
- Article
Corrections and comments
- Commented on by
Authors and funding
26 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In 2015, we implemented an at-home allogeneic haematopoietic cell transplant (allo-HCT) program. Between 2015 and 2018, 252 patients underwent allo-HCT; 41 patients underwent allo-HCT in the at-home program (46% myeloablative; 63% unrelated donor; 32% posttransplant cyclophosphamide), and these patients were compared with 39 in-patients; safety, capacity to release beds for other programs, and economic efficiency cost were evaluated. We observed a lower incidence of febrile neutropenia in the at-home group compared with that in the in-patient group (32% versus 90%; p < 0.0001), whereas the incidence of aspergillosis was similar among groups (at-home 1% versus in-patient 3%; p = 0.5). The at-home patients showed a lower incidence of 1-year severe graft-versus-host disease (GVHD; 10% versus 29%; p = 0.03). There were no differences in 1-year transplant-related mortality, relapse, or overall survival among groups. The re-admission rate in the at-home group was 7%. The at-home setting was less expensive (9087 €/transplant), and its implementation increased capacity by 10.5 allo-HCTs/year. Moreover, a chimeric antigen receptor T-cell program could be established without increasing beds. Thus, our at-home allo-HCT program may be a safe modality to reduce febrile neutropenia and acute GVHD, resulting in lower re-admission rates.
Indexed as
Identifiers
31932656What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.